NCT05388981View on ClinicalTrials.gov

Study of Single Doses of SBT115301 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

January 3, 2024

Study Completion Date

January 3, 2024

Conditions

Safety

Interventions

BIOLOGICAL

SBT115301

Immunomodulatory dimeric fusion protein

BIOLOGICAL

Placebo

Matched placebo

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors

lead

Sonoma Biotherapeutics, Inc.

INDUSTRY